- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02005744
A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function
A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function Compared With Normal Hepatic Function
Studieoversigt
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
-
Soeul, Korea, Republikken
- Yonsei University Severance Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
A. Inclusion Criteria
[The subjects with impaired hepatic function]
- The subjects who are 19 to 64 years old
- The subjects with stable hepatic disease and impaired hepatic function as Child-Pugh A or B
- Body Weight ≥ 55kg
- If females, Negative for pregnancy test at the screening and pre dose of Day 1
- The subjects who agreed with performing contraception during the study
- The subjects who agreed with written informed consent
[The subjects with normal hepatic function]
- The subjects who are 19 to 64 years old
- The subjects who are matched impaired hepatic function by gender, age(± 5years) and body weight(± 10kg)
- If females, Negative for pregnancy test at the screening and pre dose of Day 1
- The subjects who agreed with performing contraception during the study
- The subjects who agreed with written informed consent
B. exclusion criteria
[The subjects with impaired hepatic function]
- The subjects with impaired hepatic function as Child-Pugh C
- The subjects had a portosystemic shunt surgery
- The subjects had a liver transplantation or unsuitable for the study by the investigator's judgement(for examples, hepatic encephalopathy grade 3 or 4, stroke, heart failure, cancer etc.) but The subject is eligible to participate if had not chemotherapy or radiofrequency ablation therapy within 6months)
- The subjects have a gastrointestinal disease or surgery which can be effected in absorption of Investigational product
- The subjects who took drugs or medicine which can be effected in metabolism of Cytochrome P450 within 14days prior to Day 1
- Positive for anti-HIV Ab or venereal disease research laboratory etc.
[The subjects with normal hepatic function]
- The subjects with liver disease or abnormal Laboratory test(Asparate transaminase >1.25 fold of upper normal limit, Alanine transaminase>1.25 fold of upper normal limit, Total bilirubin >1.5 fold of upper normal limit)
- The subjects have a gastrointestinal disease or surgery which can be effected in absorption of Investigational product
- Estimated Glomerular filtration rate < 60 mL/min/1.73m2 by Modification of Diet in Renal Disease formula
- Positive for HBsAg, anti-Hepatitis C virus Ab, anti-HIV Ab or venereal disease research laboratory
- The subjects with high blood pressure or low blood pressure(systolic blood pressure >150mmHg or <100mmHg, diastolic blood pressure>90mmHg or <60mmHg)
- The subjects who took drugs or medicine which can be effected in metabolism of Cytochrome P450 within 14days prior to Day 1 etc.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Tildeling: Ikke-randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Child Pugh A
CKD-501 will be administered to patients who are included Child Pugh A
|
CKD-501 0.5mg, PO(per oral), once
Andre navne:
|
|
Eksperimentel: Child Pugh B
CKD-501 will be administered to patients who are included Child Pugh B
|
CKD-501 0.5mg, PO(per oral), once
Andre navne:
|
|
Eksperimentel: Subject who are matched Child Pugh A
CKD-501 will be administered to the Subjects who are matched Child Pugh A
|
CKD-501 0.5mg, PO(per oral), once
Andre navne:
|
|
Eksperimentel: Subject who are matched Child Pugh B
CKD-501 will be administered to the subjects who are matched Child Pugh B
|
CKD-501 0.5mg, PO(per oral), once
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Area Under the Concentration(last) and Cmax of CKD-501
Tidsramme: 0 to 48 hours
|
Sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 |
0 to 48 hours
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Tmax, Area Under the Concentration(inf), T1/2 and Clearance/F of CKD-501 and its metabolite
Tidsramme: 0 to 48 hours
|
Sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 |
0 to 48 hours
|
|
Fraction Unbound of CKD-501 and its metabolite
Tidsramme: 1 and 8 hours
|
sampling timepoint(hours) : 1, 8 |
1 and 8 hours
|
|
Area Under the Concentration(last) and Cmax of the metabolite
Tidsramme: o to 48 hours
|
sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 |
o to 48 hours
|
|
Metabolic ratio(metabolite/CKD-501)
Tidsramme: 0 to 48 hours
|
sampling timepoint(hours) : 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 |
0 to 48 hours
|
Andre resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Vital signs
Tidsramme: up to 8 days
|
up to 8 days
|
|
Physical examination
Tidsramme: up to 8 days
|
up to 8 days
|
|
Laboratory tests
Tidsramme: up to 8 days
|
up to 8 days
|
|
Adverse events
Tidsramme: up to 8 days
|
up to 8 days
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 19HI13018
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Leverdysfunktion
-
National Health Research Institutes, TaiwanRekrutteringMindfulness | Senlivsdepression | Voksne for sent liv | Prodromal depression af sent liv | HjernestimuleringsinterventionTaiwan
-
Universidad Complutense de MadridRekruttering
-
L'OrealRekrutteringPigmentering fra det virkelige livIndien
-
Université de Reims Champagne-ArdenneAfsluttetAdolescentes følelsesmæssige og seksuelle livFrankrig
-
Sisli Hamidiye Etfal Training and Research HospitalIkke rekrutterer endnu
-
Bournemouth UniversityDorset County Hospital NHS Foundation TrustAfsluttetErfaring, livDet Forenede Kongerige
-
University of California, Los AngelesVA Greater Los Angeles Healthcare SystemTrukket tilbageVeteranfamilier | Familiekommunikation | Civilt liv reintegrationForenede Stater
-
Swiss Federal Institute of TechnologyAfsluttetÆldret | Uafhængigt livSchweiz
-
Diakonie Kliniken ZschadraßChemnitz University of TechnologyAfsluttetMantra meditation | Mantra Meditation + Kropsorienteret Yoga | Mantra Meditation + Etisk Liv | Mantra Meditation + Kropsorienteret Yoga + Etisk LivTyskland
-
CalydialOZ'IRIS SantéAfsluttetPatientengagement | Patientdeltagelse | Patienttilfredshed | Dialyse | Patientforhold, Sygeplejerske | Erfaring, livFrankrig
Kliniske forsøg med CKD-501
-
Chong Kun Dang PharmaceuticalAfsluttetType 2 diabetes mellitusKorea, Republikken
-
Chong Kun Dang PharmaceuticalAfsluttetType 2 diabetesKorea, Republikken
-
Chong Kun Dang PharmaceuticalAfsluttetDiabetes mellitus, type 2Korea, Republikken
-
Chong Kun Dang PharmaceuticalAfsluttetType 2 diabetesKorea, Republikken
-
Chong Kun Dang PharmaceuticalAfsluttetType 2 diabetes mellitusKorea, Republikken
-
Chong Kun Dang PharmaceuticalAfsluttetSund og rask | Nedsat nyrefunktionKorea, Republikken
-
Chong Kun Dang PharmaceuticalAfsluttetType 2 diabetesKorea, Republikken
-
Chong Kun Dang PharmaceuticalUkendtType 2 diabetes mellitusKorea, Republikken
-
Chong Kun Dang PharmaceuticalAfsluttetType 2 DiabetesKorea, Republikken
-
Chong Kun Dang PharmaceuticalAfsluttetDiabetes mellitus, type IIKorea, Republikken